Stamakort
GI HealthAlso known as: Stomach Bioregulator, Khavinson Stomach Peptide, Gastric Bioregulator
Mechanism
Stamakort is a peptide bioregulator targeting the stomach lining (gastric mucosa). It aims to support the health and regeneration of the cells that produce stomach acid, digestive enzymes, and the protective mucus layer. This is relevant for age-related digestive decline, chronic gastritis, and recovery from H. pylori damage. Many people over 50 produce insufficient stomach acid (hypochlorhydria), leading to poor nutrient absorption — Stamakort aims to normalize this function at the gene expression level.
Technical detail
Stamakort is a short-chain peptide bioregulator from the Khavinson series targeting gastric mucosal cells — including parietal cells (HCl secretion), chief cells (pepsinogen), mucous neck cells (mucin/bicarbonate barrier), and G cells (gastrin). Proposed mechanism: interaction with gene promoter regions in gastric epithelial cell nuclei to normalize expression of H+/K+ ATPase (proton pump) in parietal cells, pepsinogen isoenzymes in chief cells, and MUC5AC/MUC6 mucin genes for mucosal barrier integrity. May modulate gastrin/somatostatin balance and support gastric stem cell niche (isthmus region) for mucosal turnover. Relevant to age-associated atrophic gastritis and post-H. pylori gastric mucosal recovery. Published data limited to Khavinson group.
Effects
GI: Primary target system. The gastric mucosa is one of the most rapidly renewing tissues in the body — entire surface epithelium turns over every 3-5 days. Contains: (1) Parietal cells — produce HCl (stomach acid) via H+/K+ ATPase (proton pump); acid output declines ~1% per year after age 40 (hypochlorhydria); (2) Chief cells — produce pepsinogen for protein digestion; (3) Mucous neck cells — produce the bicarbonate-mucus barrier that protects the stomach from its own acid; (4) G cells — produce gastrin, the hormone that stimulates acid secretion; (5) D cells — produce somatostatin, which inhibits acid secretion (negative feedback). Age-related atrophic gastritis affects 20-30% of people over 60 — chronic inflammation leads to loss of parietal and chief cells, reduced acid output, impaired protein digestion, and vitamin B12/iron/calcium malabsorption. Stamakort targets gastric mucosal cells to normalize gene expression. METABOLIC: Hypochlorhydria causes B12 deficiency (B12 requires acid for absorption from food), iron deficiency anemia, and calcium malabsorption (contributing to osteoporosis). Proper gastric acid is essential for protein digestion and amino acid absorption — affects muscle protein synthesis. IMMUNE: Gastric acid is the first line of defense against ingested pathogens. Hypochlorhydria increases risk of C. difficile, H. pylori persistence, Salmonella, and small intestinal bacterial overgrowth (SIBO). NEUROLOGICAL: B12 deficiency from hypochlorhydria causes neurological symptoms (peripheral neuropathy, cognitive decline, depression). Tier 3: Users report improved digestion, reduced bloating, better B12 levels, and reduced SIBO symptoms.
Practitioner Guide
DOSING TIPS: Standard protocol: 1-2 capsules daily for 10-30 days, repeated every 3-6 months. Take before meals. For active gastric concerns: 2 capsules daily for 30 days. SUPPLEMENT SYNERGIES: Betaine HCl with pepsin (650mg with protein-containing meals) — provides immediate acid support while bioregulator works on cellular level. Zinc-carnosine (37.5mg zinc-carnosine twice daily) — evidence-based gastroprotective, supports mucosal healing. Deglycyrrhizinated licorice (DGL, 400mg before meals) — stimulates mucus production and mucosal defense. Mastic gum (1000mg/day) — traditional H. pylori treatment. Vitamin B12 (methylcobalamin 1000-5000mcg sublingual) if deficient. CYCLING: Standard Khavinson protocol. CONTRAINDICATION NUANCES: Active peptic ulcer disease — treat with standard therapy (PPI + antibiotics if H. pylori positive) before or alongside bioregulator. Gastric cancer — do not stimulate gene expression in neoplastic tissue. Patients on PPIs — bioregulator aims to restore natural acid production, which is antagonistic to PPI goal; discuss with gastroenterologist. Zollinger-Ellison syndrome — do not stimulate gastrin or acid. STORAGE: Room temperature. PATIENT EDUCATION: Many digestive problems after age 50 come from too LITTLE stomach acid, not too much. Low acid means poor protein digestion, vitamin malabsorption (especially B12 and iron), and increased bacterial infections in the gut. This bioregulator aims to restore your stomach's ability to produce the right amount of acid and enzymes. Get a gastric pH test or Heidelberg capsule test if possible.
Research Summary
TIER 1 (Gold Standard): No Western clinical trials specific to Stamakort. TIER 2 (Strong): Khavinson bioregulation theory. Age-related atrophic gastritis and hypochlorhydria well-characterized (Gastroenterology, AGA guidelines). Prevalence data: 20-30% of elderly have atrophic gastritis. TIER 3 (Moderate): Khavinson group gastric bioregulator publications. Practitioner and community reports. KEY FINDINGS: (1) Gastric mucosa has high regenerative capacity, making it an ideal bioregulator target. (2) Hypochlorhydria is underdiagnosed and has cascading nutrient deficiency effects. (3) No independent validation of Stamakort specifically. GAPS: Standard Khavinson gaps.